GE launches new MRI contrast agent at ECR 2017

GE Healthcare is launching its new Clariscan (gadoteric acid) MRI contrast agent at this week's ECR 2017 meeting in Vienna.

The gadolinium-based contrast agent (GBCA) is designed to visualize abnormalities in the brain, spine, and associated tissues. The macrocyclic and ionic contrast agent will be available in a range of doses in vials and prefilled syringes, and it joins the company's linear GBCA Omniscan, which has been used for MR imaging for more than 25 years.

Thus far, Clariscan has received approval for marketing and distribution in Norway. GE plans to introduce the new contrast agent to the rest of Europe this year.

Pancreas Imaging Fellowship
November 19, 2023November 21, 2023
Artificial intelligence in radiology workflow
November 14, 2023November 16, 2023
Online Pelvic Floor Imaging Fellowship
November 19, 2023November 21, 2023
Page 1 of 126
Next Page